Veritas Investment Management LLP boosted its stake in Thermo Fisher Scientific Inc (NYSE:TMO) by 2.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 420,003 shares of the medical research company’s stock after purchasing an additional 8,149 shares during the period. Thermo Fisher Scientific comprises about 10.7% of Veritas Investment Management LLP’s holdings, making the stock its 3rd largest holding. Veritas Investment Management LLP owned about 0.10% of Thermo Fisher Scientific worth $79,454,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other large investors also recently modified their holdings of TMO. Putnam FL Investment Management Co. lifted its stake in Thermo Fisher Scientific by 417.4% in the 1st quarter. Putnam FL Investment Management Co. now owns 18,558 shares of the medical research company’s stock valued at $2,850,000 after purchasing an additional 14,971 shares during the last quarter. MARSHALL WACE ASIA Ltd bought a new position in Thermo Fisher Scientific in the 1st quarter valued at approximately $35,578,000. Marshall Wace North America L.P. bought a new position in Thermo Fisher Scientific in the 1st quarter valued at approximately $35,578,000. Tekla Capital Management LLC increased its position in Thermo Fisher Scientific by 61.6% in the 1st quarter. Tekla Capital Management LLC now owns 228,020 shares of the medical research company’s stock valued at $35,024,000 after acquiring an additional 86,900 shares during the period. Finally, Meiji Yasuda Asset Management Co Ltd. increased its position in Thermo Fisher Scientific by 7.6% in the 1st quarter. Meiji Yasuda Asset Management Co Ltd. now owns 35,745 shares of the medical research company’s stock valued at $5,490,000 after acquiring an additional 2,522 shares during the period. 86.16% of the stock is owned by institutional investors and hedge funds.
In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 50,000 shares of the firm’s stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $188.39, for a total value of $9,419,500.00. Following the transaction, the chief executive officer now directly owns 252,577 shares of the company’s stock, valued at $47,582,981.03. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.49% of the stock is currently owned by company insiders.
Several research firms have recently weighed in on TMO. Jefferies Group reiterated a “hold” rating and set a $195.00 price objective on shares of Thermo Fisher Scientific in a research report on Thursday, September 28th. Leerink Swann reiterated an “outperform” rating and set a $200.00 price objective (down from $216.00) on shares of Thermo Fisher Scientific in a research report on Monday. Goldman Sachs Group assumed coverage on shares of Thermo Fisher Scientific in a research report on Tuesday, September 26th. They set a “buy” rating and a $225.00 price objective for the company. Barclays restated an “overweight” rating and issued a $215.00 price target (up from $200.00) on shares of Thermo Fisher Scientific in a report on Monday, September 25th. Finally, Argus restated a “buy” rating on shares of Thermo Fisher Scientific in a report on Tuesday, August 22nd. They noted that the move was a valuation call. One investment analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $205.21.
Thermo Fisher Scientific Inc (NYSE:TMO) traded down $10.17 during trading hours on Tuesday, reaching $182.03. 3,926,700 shares of the company’s stock were exchanged, compared to its average volume of 1,555,471. Thermo Fisher Scientific Inc has a 1-year low of $139.88 and a 1-year high of $201.20. The firm has a market capitalization of $77,071.31, a PE ratio of 21.12, a price-to-earnings-growth ratio of 1.76 and a beta of 1.06. The company has a debt-to-equity ratio of 0.85, a current ratio of 1.26 and a quick ratio of 0.81.
Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, October 25th. The medical research company reported $2.31 earnings per share for the quarter, beating analysts’ consensus estimates of $2.24 by $0.07. Thermo Fisher Scientific had a net margin of 11.73% and a return on equity of 15.94%. The firm had revenue of $5.12 billion for the quarter, compared to analyst estimates of $5.03 billion. During the same period last year, the firm earned $2.03 earnings per share. The business’s quarterly revenue was up 13.9% compared to the same quarter last year. research analysts forecast that Thermo Fisher Scientific Inc will post 9.36 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, January 15th. Shareholders of record on Friday, December 15th will be paid a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.33%. The ex-dividend date is Thursday, December 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.19%.
TRADEMARK VIOLATION NOTICE: This piece was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2017/12/05/veritas-investment-management-llp-raises-stake-in-thermo-fisher-scientific-inc-tmo.html.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.